论文部分内容阅读
目的探讨度洛西汀治疗癌症抑郁患者的临床疗效。方法采用前瞻性随机开放试验方法,将60例癌症抑郁患者分为度洛西汀和氟西汀组各30例,观察治疗6wk。于治疗前及治疗1、2、4、6 wk末采用汉密尔顿抑郁量表(HAMD)和焦虑量表(HAMA)评定疗效,用副反应量表(TESS)评定药物不良反应,根据卡氏功能量表(KPS)进行生活质量评估。结果 HAMD和HAMA评分显示,与治疗前相比,度洛西汀组治疗1wk末起评分有显著下降(P<0.05),氟西汀组治疗2wk末起评分有显著下降(P<0.05),2组评分同期比较1、2 wk末均有显著差异(P<0.05);2组在6wk末疗效、生活质量和不良反应方面均无显著差异(P>0.05)。结论度洛西汀治疗癌症抑郁疗效与氟西汀相当,但起效更快,耐受性好。
Objective To investigate the clinical efficacy of duloxetine in the treatment of patients with cancer depression. Methods By prospective randomized open trial, 60 patients with cancer depression were divided into duloxetine and fluoxetine group, 30 cases each for 6 weeks. Before treatment and at the end of treatment for 1, 2, 4 and 6 wk, the Hamilton Depression Rating Scale (HAMD) and Anxiety Scale (HAMA) were used to evaluate the curative effect. TESS was used to evaluate adverse drug reactions. Table (KPS) quality of life assessment. Results The scores of HAMD and HAMA showed that the score of duloxetine group decreased significantly from the end of 1wk to the end of treatment (P <0.05), and the score of fluoxetine group decreased significantly from the end of 2wk (P <0.05) There was significant difference between the two groups at the end of 1 and 2 weeks (P <0.05). There was no significant difference between the two groups in efficacy at the end of 6 weeks, quality of life and adverse reactions (P> 0.05). Conclusion Duloxetine is effective in treating cancer depression with fluoxetine, but its effect is faster and better tolerated.